MARLBOROUGH, Mass., March 25, 2019 /PRNewswire/ -- Phio Pharmaceuticals Corp. (PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform, announced today that the Company will present a poster at the American Association for Cancer Research (AACR) Annual Meeting 2019, which will be held from March 29–April 1, 2019 at the Georgia World Congress Center in Atlanta, Georgia.
The details of the presentation are as follows:
Poster #: 1963
Poster Title: Feasibility and efficacy using self-delivering RNAi against TGFB1 to reduce TME immunosuppression
Session: Secreted Changes in the Tumor Microenvironment: Exosomes and Chemokines
Date and Time: Monday, April 1, 2019, 1:00 p.m.–5:00 p.m. Eastern Time
Location: Hall B, Poster Section 6
The poster will be presented by Dr. Winnie Tam, Director of Pharmacology, and will also be available under the "Investors–Events and Presentations" section of the Company's website, www.phiopharma.com, approximately one hour following the presentation.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (sd-rxRNA®) therapeutic platform. The Company's discovery and research efforts are focused on developing sd-rxRNA therapeutic compounds to be used in the context of adoptive cell transfer by targeting checkpoints or other gene targets, or to be used in immunotherapy following intratumoral injection. We aim to maximize the power of our sd-rxRNA therapeutic compounds by weaponizing therapeutic immune effector cells to attack cancer, and to make tumors more susceptible to such attacks, and ultimately provide patients battling cancers with a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. These statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the safety and efficacy of our product candidates, future success of our clinical trials and scientific studies, expected duration of available cash runway, our ability to enter into strategic partnerships and the future success of these strategic partnerships, the availability of funds and resources to pursue our research and development projects and general economic conditions. Our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q include detailed risks under the caption "Risk Factors" that may affect our business, results of operations and financial condition. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.
Phio Pharmaceuticals Corp.
View original content:http://www.prnewswire.com/news-releases/phio-pharmaceuticals-to-present-poster-on-the-use-of-self-delivering-rnai-in-immuno-oncology-at-the-aacr-annual-meeting-2019-300817442.html